Exclusive Partner Agreement for Austrian Market
Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces it has secured a new long term exclusive distribution deal in Austria with a new partner for its Procto-eze range.
Germania Pharmazeutika GesmbH (“Germania”) is a privately owned pharmaceutical company focused on products specifically for women’s health, diabetes and gastro related issues. Germania will launch all products in the Procto-eze range in 2018. The range comprises of three products: cleanser, cream and wipes. These provide a comprehensive treatment regimen for haemorrhoids and anal irritation for men and women.
Separately, the Company announces that it has received a patent grant for its UltraDEX Sensitive range in Indonesia. This further strengthens its patent base for UltraDEX Sensitive, as the Company continues its search for international partners. UltraDEX Sensitive will launch next in the Nordic regions in Q1 2018 and final launch plans are in the process of being completed.
Jerry Randall, commented:
“I am delighted with the appointment of another exclusive long-term partner for the Procto-eze range in an important EU market. This innovative range of products is beginning to get traction in a number of international markets. We continue to see strong levels of interest in our branded portfolio and expect a continued flow of new partner announcements in the future. In addition, the patent grant in Indonesia adds to the patent estate surrounding the UltraDEX Sensitive range that we currently have already in the EU, USA and many other markets, building on this valuable asset.”
Venture Life Investors Video